http://www.deadpresident.blogspot.com
India's outsourcing rev growth softening: TCS
Post Session Commentary - June 18 2008
Market slips after two-session rally
Political worries pull market down
Grey Market - Avon Weighing zooms
A dull day at US Market
Gold dives, losses limited on mixed US data
Inox Leisure / Mcnally Bharat, Godawari Power, Steel Pipes
Welspun Gujarat Stahl Rohren / Mukand Ltd
Jindal SAW /ABG Shipyard /Tech Mahindra
IDBI /Steel Sector
--------------------------------------------------
http://www.vccircle.com
The Singhs’ Rs 10,000 Crore Plan: Banking & Private Equity
Anil Ambani Close To Investing $600M In JV With Spielberg’s DreamWorks: WSJ
Kubera Partners To Invest $22 Million In Media Infrastructure Company Essel Shyam Telelink
Defence-Focused India Rizing Fund Gets Govt Nod To Raise $130M From Overseas
ICICI Venture To Exit Avesthagen: Report
GE Money Stake Sale Plans Come A Cropper Over Valuations
S. Kumars To Acquire Companies in Europe, North America
VCC Digest: Bulk Deal Is A Big Deal, Sahara Gets Reprieve, Pfizer Is Red Herring
UTI Ventures Puts In $20 Million Of The $60 Million Round In Deepak Cables
Prudential Real Estate Investors Forms JV With Beekman Helix In India
Motilal Oswal VC Invests Rs 40 Cr In Consumer Durable Maker Dixon Technologies
The Acquirer Gets Acquired: Dubai’s Al Rostamani To Buy 35% In GHCL
Goldman Sachs PE Invests In Engineering, Plumbing Firm Sterling & Wilson
Government-Owned Balmer Lawrie To Acquire Stake In Travel & Tour Operator
Helion, Opus Back Online Video Ad Network Jivox With $10.7M
Avigo Capital Partners Says It’s In For long Term; ING Looks For PE Firms
Carlyle Hires Ex-Citi Executive Sunil Kaul For Asia Investments
----------------------------------------------------
www.indiape.com
Foreign investors may shun real estate
VCs now take a shot at defence sector
Maneesh Pharma buys 51% stake in US firm Synovics
Private equity players still chases infrastructure profits
Deal makers carve their space in VC, PE business
Balmer Lawrie set to buy 50% in travel firm
TCI to sell 10% stake to fund growth plans
Goldman buys into Shapoorji Pallonji arm
Reliance eyeing stake in Jet Airways
KSK Energy Ventures raises Rs 415 cr via pre-IPO placements
ING looking to buy out private equity firm in India
Pfizer may go all out for Ranbaxy
RBI opens doors to six VC funds after long gap
Lehman Brothers Real Estate Partners to invest $175 million in Unitech's project
Gemini Comm buys Chennai firm for 70 mln rupees
Source: Above sites. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
This blog is for providing daily news of Corporate Indian Stories, Corporate Results, Equities, MFs, Banking,Insurance, Brokerages Informations, World Business, Venture Capital, Angel Investors, BSchools, MBAs,Jobs, Politics & something Interesting.Our team will be grateful to the owners of various Indian/world/govt sites to refer their sites to get INFORMATION without objection.Request viewers to make verification about the information. Blog is not responsible for any faulty information.
18 June 2008
Quarterly Results
Corporate Results
Aurobindo Pharma net profit declines 2.60% in the March 2008 quarter
Rajesh Exports net profit rises 46.79% in the March 2008 quarter
--------------------------------------------------------------
Dhanuka Agritech net profit rises 61.14% in the year ended March 2008
Sales rise 23.84% to Rs 248.21 crore
KEI Industries net profit declines 42.91% in the March 2008 quarter
Sales rise 24.33% to Rs 258.47 crore
Finolex Industries net profit declines 93.07% in the March 2008 quarter
Sales rise 39.79% to Rs 428.60 crore
Arrow Webtex net profit declines 85.14% in the March 2008 quarterSales rise 7.40% to Rs 22.34 crore
G P Electronics reports net profit of Rs 1.27 crore in the March 2008 quarterSales rise 48.23% to Rs 2.09 crore
Indian Extraction net profit rises 1428.57% in the March 2008 quarter
Volant Textile Mills reports net profit of Rs 24.17 crore in the March 2008 quarter
Hotel Leela Venture net profit declines 34.24% in the March 2008 quarter
Solar Explosives net profit rises 16.62% in the March 2008 quarter
Greenply Industries net profit rises 29.21% in the March 2008 quarter
Mafatlal Industries reports net profit of Rs 29.30 crore in the year ended March 2008GMR Ferro Alloys & Industries reports net profit of Rs 0.64 crore in the March 2008 quarter
Savant Infocomm reports net loss of Rs 0.02 crore in the March 2008 quarter
Total Exports reports net loss of Rs 0.02 crore in the March 2008 quarter
Themis Medicare net profit rises 22.22% in the March 2008 quarter
Bimetal Bearings net profit rises 30.92% in the March 2008 quarter
International Data Management reports net loss of Rs 0.01 crore in the March 2008
quarter
Rajapalayam Mills net profit declines 70.00% in the March 2008 quarter
Makers Laboratories reports net profit of Rs 0.26 crore in the March 2008 quarter
Dish TV India reports net loss of Rs 115.06 crore in the March 2008 quarter
Marmagoa Steel net profit rises 422.68% in the year ended March 2008
Indraprastha Gas net profit rises 20.24% in the March 2008 quarter
Mafatlal Finance Company reports net loss of Rs 9.04 crore in the March 2008 quarter
P I Industries net profit rises 19.08% in the March 2008 quarter
Sical Logistics net profit rises 26.40% in the March 2008 quarter
Source: www.capitalmarket.com. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
Aurobindo Pharma net profit declines 2.60% in the March 2008 quarter
Rajesh Exports net profit rises 46.79% in the March 2008 quarter
--------------------------------------------------------------
Dhanuka Agritech net profit rises 61.14% in the year ended March 2008
Sales rise 23.84% to Rs 248.21 crore
KEI Industries net profit declines 42.91% in the March 2008 quarter
Sales rise 24.33% to Rs 258.47 crore
Finolex Industries net profit declines 93.07% in the March 2008 quarter
Sales rise 39.79% to Rs 428.60 crore
Arrow Webtex net profit declines 85.14% in the March 2008 quarterSales rise 7.40% to Rs 22.34 crore
G P Electronics reports net profit of Rs 1.27 crore in the March 2008 quarterSales rise 48.23% to Rs 2.09 crore
Indian Extraction net profit rises 1428.57% in the March 2008 quarter
Volant Textile Mills reports net profit of Rs 24.17 crore in the March 2008 quarter
Hotel Leela Venture net profit declines 34.24% in the March 2008 quarter
Solar Explosives net profit rises 16.62% in the March 2008 quarter
Greenply Industries net profit rises 29.21% in the March 2008 quarter
Mafatlal Industries reports net profit of Rs 29.30 crore in the year ended March 2008GMR Ferro Alloys & Industries reports net profit of Rs 0.64 crore in the March 2008 quarter
Savant Infocomm reports net loss of Rs 0.02 crore in the March 2008 quarter
Total Exports reports net loss of Rs 0.02 crore in the March 2008 quarter
Themis Medicare net profit rises 22.22% in the March 2008 quarter
Bimetal Bearings net profit rises 30.92% in the March 2008 quarter
International Data Management reports net loss of Rs 0.01 crore in the March 2008
quarter
Rajapalayam Mills net profit declines 70.00% in the March 2008 quarter
Makers Laboratories reports net profit of Rs 0.26 crore in the March 2008 quarter
Dish TV India reports net loss of Rs 115.06 crore in the March 2008 quarter
Marmagoa Steel net profit rises 422.68% in the year ended March 2008
Indraprastha Gas net profit rises 20.24% in the March 2008 quarter
Mafatlal Finance Company reports net loss of Rs 9.04 crore in the March 2008 quarter
P I Industries net profit rises 19.08% in the March 2008 quarter
Sical Logistics net profit rises 26.40% in the March 2008 quarter
Source: www.capitalmarket.com. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
Pfizer, Ranbaxy settle Lipitor dispute: UTVi
Pfizer, Ranbaxy settle Lipitor dispute : UTVi.com
Ranbaxy, Pfizer settle Lipitor patent disputes : Reuters India
Ranbaxy Laboratories has settled most of its patent disputes with Pfizer allowing it to launch a generic version of the US group's blockbuster cholesterol drug Lipitor from November 30, 2011.
Ranbaxy also said it would have 180 days market exclusivity following the US launch of the generic version of Lipitor, the world's biggest selling drug with sales of $12.7 billion in 2007.
"This comprehensively settles outstanding issues between Ranbaxy and Pfizer bringing to closure a number of on-going patent disputes," Malvinder Mohan Singh, chief executive and managing director, Ranbaxy, said in the statement.
"This will make the world's largest selling drug more accessible to patients who will gain from the timely availability of an affordable quality option," he added.Speaking to UTVi, Singh said this is the largest and the most comprehensive settlement in the history of the pharmaceutical industry. "The best news in the deal is that it opens up a $12 billion market for Ranbaxy, and we will be getting access to the $8 billion US market from November 30, 2011.... no questions, no risks...."Ranbaxy will also have the licence to sell the drug in an additional seven countries including Canada, Belgium, the Netherlands, Germany, Sweden, Italy and Australia.A Pfizer spokesperson maintained that the settlement with Ranbaxy was pro-patent and pro-intellectual property. The spokesperson also denied any intention of buying the non-promoter stake in Ranbaxy.Ranjit Kapadia, pharma analyst at Prabhudas Lilladher, while speaking to UTVi , said the market had no whiff of the deal. "Or the market would have flared up today," he added.The deal may push the Ranbaxy stock to around Rs 650 as against the open offer price of Rs 737 to be offered by Daiichi Sankyo, which has signed a deal with the promoters of Ranbaxy. "Ranbaxy is a buy at the moment," Kapadia added.
Following is the press release issued by RanbaxyRANBAXY AND PFIZER SETTLE LIPITOR LITIGATION WORLDWIDE
* Ranbaxy will Market Generic Atorvastatin in the U.S. with 180 Days Exclusivity from Nov. 30, 2011
* Agreement Also Resolves Caduet, Accupril Litigation in the US
Gurgaon, Harayana, India; Princeton, NJ, USA – June 18 , 2008 -- Ranbaxy Laboratories Limited (Ranbaxy), announced today that it has entered into an agreement with Pfizer Inc. to settle most of the patent litigation worldwide involving Atorvastatin (Lipitor), the world’s most-prescribed cholesterol-lowering medicine. This decision will allow for an earlier introduction of a generic formulation that will benefit patients and many healthcare systems throughout the world. Lipitor is the world's largest selling drug with worldwide sales in 2007 of $12.7 billion.
The agreement pertains solely to Ranbaxy and its affiliates and does not cover legal challenges to the Lipitor patents involving other generic manufacturers. However, as Ranbaxy was the first generic challenger to the listed Lipitor patents, it retains the right to the marketing exclusivity of 180 days in the United States. Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Atorvastatin and the fixed-dose combination of Atorvastatin-Amlodipine besylate in the United States effective Nov. 30, 2011.
Welcoming the development, Malvinder Mohan Singh, CEO and MD, Ranbaxy Laboratories Ltd., said, “This comprehensively settles outstanding issues between Ranbaxy and Pfizer bringing to closure a number of ongoing patent disputes. It also provides certainty and visibility to the launch of Ranbaxy’s Generic Atorvastatin, with180 day market exclusivity in the US and an early entry in other markets. This will make the worlds largest selling drug more accessible to patients who will gain from the timely availability of an affordable quality option.”
Ranbaxy will also have a license to sell Atorvastatin on varying dates in an additional 7 countries, including: Canada, Belgium, Netherlands, Germany, Sweden, Italy and Australia. Ranbaxy and Pfizer have also resolved their disputes regarding Atorvastatin in Malaysia, Brunei, Peru and Vietnam.
In addition, the lawsuits between Pfizer and Ranbaxy regarding Atorvastatin will be dismissed in select countries and the lawsuits between Pfizer and Ranbaxy regarding the fixed dose combination product containing Atorvastatin and amlodipine will be dismissed in the U.S. and Ranbaxy will no longer contest the validity of Pfizer’s patents in such countries. Such patent challenges by Ranbaxy regarding Lipitor have been underway in numerous markets since 2003.
The Atorvastatin patents involved in this agreement are the basic compound patent, which expires in the United States in 2010; the enantiomer patent, which expires in the United States in 2011; and various process and crystalline form patents, which expire in 2016 and 2017; and the combination patent for fixed-dose combination product which expires in 2018.
The agreement also covers the fixed-dose combination of Atorvastatin-Amlodipine besylate (presently marketed under the brand Caduet, which also contains crystalline Form I Atorvastatin), a fixed-dose combination product indicated for patients suffering from both high blood pressure and high levels of cholesterol. The patent for the fixed-dose combination expires in 2018. The settlement also resolves additional patent litigation between the companies involving the branded drugs Accupril (in the U.S.) and Viagra (in Ecuador) and all patent litigation with Ranbaxy relating to generic formulation of Quinapril hydrochloride in the United States and Sildenafil in Ecuador.
Litigation between Ranbaxy and Pfizer relating to Lipitor will continue in five other European countries -- Finland, Spain, Portugal, Denmark and Romania.
Ranbaxy CEO sees consolidation wave over 3 years
Source: Above sites. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
Ranbaxy, Pfizer settle Lipitor patent disputes : Reuters India
Ranbaxy Laboratories has settled most of its patent disputes with Pfizer allowing it to launch a generic version of the US group's blockbuster cholesterol drug Lipitor from November 30, 2011.
Ranbaxy also said it would have 180 days market exclusivity following the US launch of the generic version of Lipitor, the world's biggest selling drug with sales of $12.7 billion in 2007.
"This comprehensively settles outstanding issues between Ranbaxy and Pfizer bringing to closure a number of on-going patent disputes," Malvinder Mohan Singh, chief executive and managing director, Ranbaxy, said in the statement.
"This will make the world's largest selling drug more accessible to patients who will gain from the timely availability of an affordable quality option," he added.Speaking to UTVi, Singh said this is the largest and the most comprehensive settlement in the history of the pharmaceutical industry. "The best news in the deal is that it opens up a $12 billion market for Ranbaxy, and we will be getting access to the $8 billion US market from November 30, 2011.... no questions, no risks...."Ranbaxy will also have the licence to sell the drug in an additional seven countries including Canada, Belgium, the Netherlands, Germany, Sweden, Italy and Australia.A Pfizer spokesperson maintained that the settlement with Ranbaxy was pro-patent and pro-intellectual property. The spokesperson also denied any intention of buying the non-promoter stake in Ranbaxy.Ranjit Kapadia, pharma analyst at Prabhudas Lilladher, while speaking to UTVi , said the market had no whiff of the deal. "Or the market would have flared up today," he added.The deal may push the Ranbaxy stock to around Rs 650 as against the open offer price of Rs 737 to be offered by Daiichi Sankyo, which has signed a deal with the promoters of Ranbaxy. "Ranbaxy is a buy at the moment," Kapadia added.
Following is the press release issued by RanbaxyRANBAXY AND PFIZER SETTLE LIPITOR LITIGATION WORLDWIDE
* Ranbaxy will Market Generic Atorvastatin in the U.S. with 180 Days Exclusivity from Nov. 30, 2011
* Agreement Also Resolves Caduet, Accupril Litigation in the US
Gurgaon, Harayana, India; Princeton, NJ, USA – June 18 , 2008 -- Ranbaxy Laboratories Limited (Ranbaxy), announced today that it has entered into an agreement with Pfizer Inc. to settle most of the patent litigation worldwide involving Atorvastatin (Lipitor), the world’s most-prescribed cholesterol-lowering medicine. This decision will allow for an earlier introduction of a generic formulation that will benefit patients and many healthcare systems throughout the world. Lipitor is the world's largest selling drug with worldwide sales in 2007 of $12.7 billion.
The agreement pertains solely to Ranbaxy and its affiliates and does not cover legal challenges to the Lipitor patents involving other generic manufacturers. However, as Ranbaxy was the first generic challenger to the listed Lipitor patents, it retains the right to the marketing exclusivity of 180 days in the United States. Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Atorvastatin and the fixed-dose combination of Atorvastatin-Amlodipine besylate in the United States effective Nov. 30, 2011.
Welcoming the development, Malvinder Mohan Singh, CEO and MD, Ranbaxy Laboratories Ltd., said, “This comprehensively settles outstanding issues between Ranbaxy and Pfizer bringing to closure a number of ongoing patent disputes. It also provides certainty and visibility to the launch of Ranbaxy’s Generic Atorvastatin, with180 day market exclusivity in the US and an early entry in other markets. This will make the worlds largest selling drug more accessible to patients who will gain from the timely availability of an affordable quality option.”
Ranbaxy will also have a license to sell Atorvastatin on varying dates in an additional 7 countries, including: Canada, Belgium, Netherlands, Germany, Sweden, Italy and Australia. Ranbaxy and Pfizer have also resolved their disputes regarding Atorvastatin in Malaysia, Brunei, Peru and Vietnam.
In addition, the lawsuits between Pfizer and Ranbaxy regarding Atorvastatin will be dismissed in select countries and the lawsuits between Pfizer and Ranbaxy regarding the fixed dose combination product containing Atorvastatin and amlodipine will be dismissed in the U.S. and Ranbaxy will no longer contest the validity of Pfizer’s patents in such countries. Such patent challenges by Ranbaxy regarding Lipitor have been underway in numerous markets since 2003.
The Atorvastatin patents involved in this agreement are the basic compound patent, which expires in the United States in 2010; the enantiomer patent, which expires in the United States in 2011; and various process and crystalline form patents, which expire in 2016 and 2017; and the combination patent for fixed-dose combination product which expires in 2018.
The agreement also covers the fixed-dose combination of Atorvastatin-Amlodipine besylate (presently marketed under the brand Caduet, which also contains crystalline Form I Atorvastatin), a fixed-dose combination product indicated for patients suffering from both high blood pressure and high levels of cholesterol. The patent for the fixed-dose combination expires in 2018. The settlement also resolves additional patent litigation between the companies involving the branded drugs Accupril (in the U.S.) and Viagra (in Ecuador) and all patent litigation with Ranbaxy relating to generic formulation of Quinapril hydrochloride in the United States and Sildenafil in Ecuador.
Litigation between Ranbaxy and Pfizer relating to Lipitor will continue in five other European countries -- Finland, Spain, Portugal, Denmark and Romania.
Ranbaxy CEO sees consolidation wave over 3 years
Source: Above sites. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
17 June 2008
ET Stories and Results
http://economictimes.indiatimes.com/
Inflation may hit double-digit:
RBI allows Sahara to accept deposits maturing till June 2011
World will run out of Internet addresses by 2010
Nifty June discount widens / Voltas buys 50 pc stake in JV firm with Fedders International
Tata Steel forms JV for Orissa power project
KEC secures Rs 160 cr contract from NTPC
L&T in talks to acquire Crompton's projects biz
Sensex adds 300 pts on global cues, short covering
FIIs invest in shares worth Rs 142.36 crore
------------------------------
Rediff.com
Anil Ambani eyes over 40% MTN pie
• Spotted: Warren Buffet in Omaha • Warren Buffett's 6 smart tips
• Ganesh Natarajan's Tech Blog• All about insider trading
• States to roll back jet fuel tax cuts• How oil prices are hurting economy
--------------------------------
Results from Indiaearnings.com
Tata Comm Q4 stand net profit at Rs 58.9 cr
BPCL Q4 net profit at Rs 58.4 cr
Zee Entertainment FY08 net profit at Rs 416 cr
SREI Infra FY08 net profit at Rs 135 cr
Source: Above sites. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
Labels:
ET,
Rediff Stories and Results
Goyal in talks for Jet stake sale and other Stories from UTVi
Goyal in talks for Jet stake sale
Naresh Goyal is left with little choice but to share his precious stake in the country's largest private airline Jet Airways. Sources tell UTVi that Goyal is in preliminary talks with steel baron Lakshmi N. Mittal and telecom czar Sunil Mittal for a stake sale.
After refusing to dilute his 80% promoter stake till about a year back, experts say Goyal may now be willing to bring his stake down to 51%. They also say aviation in India has great potential, and it may make sense for big businessmen with deep pockets to invest in it at this stage when valuations are plummeting. Investment bankers say Jet could fetch a valution of $1.5-2 billion.
Jayesh Desai, director, Ernst and Young, says: "Jet is still one of the most successful airlines in the Indian aviation market. People like Sunil Mittal and Lakshmi N. Mittal would be keen to participate in the growth story of the Indian aviation market."
This comes after Goyal has exhausted all other options of raising money. He has had little luck with private equity players who are not willing to give the valuations Goyal has been demanding. The capital markets have been playing spoil sport for Jet - it has not managed to rasie $400 million through the rights issue that has been indefinitely deferred.
Desai adds: "Investors have been shying away from Indian airlines but Jet could be a standard core infrastructure investment..." Jet Airways, like other airlines, is currently struggling, and it has already put its international expansion on hold. The airline is also cutting all possible corners to reduce costs.
Other UTVi stories:
Sensex ends up 300pts, HDFC gains 6%
Buzzing stocks: Sasken, Piramal Life
RBI gives Sahara 7 yrs to repay deposits
BPCL FY08 net down 17% to Rs 1,769cr
Deposit rates move up
McCain supports India in G-8
Source: http://www.utvi.com. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
Naresh Goyal is left with little choice but to share his precious stake in the country's largest private airline Jet Airways. Sources tell UTVi that Goyal is in preliminary talks with steel baron Lakshmi N. Mittal and telecom czar Sunil Mittal for a stake sale.
After refusing to dilute his 80% promoter stake till about a year back, experts say Goyal may now be willing to bring his stake down to 51%. They also say aviation in India has great potential, and it may make sense for big businessmen with deep pockets to invest in it at this stage when valuations are plummeting. Investment bankers say Jet could fetch a valution of $1.5-2 billion.
Jayesh Desai, director, Ernst and Young, says: "Jet is still one of the most successful airlines in the Indian aviation market. People like Sunil Mittal and Lakshmi N. Mittal would be keen to participate in the growth story of the Indian aviation market."
This comes after Goyal has exhausted all other options of raising money. He has had little luck with private equity players who are not willing to give the valuations Goyal has been demanding. The capital markets have been playing spoil sport for Jet - it has not managed to rasie $400 million through the rights issue that has been indefinitely deferred.
Desai adds: "Investors have been shying away from Indian airlines but Jet could be a standard core infrastructure investment..." Jet Airways, like other airlines, is currently struggling, and it has already put its international expansion on hold. The airline is also cutting all possible corners to reduce costs.
Other UTVi stories:
Sensex ends up 300pts, HDFC gains 6%
Buzzing stocks: Sasken, Piramal Life
RBI gives Sahara 7 yrs to repay deposits
BPCL FY08 net down 17% to Rs 1,769cr
Deposit rates move up
McCain supports India in G-8
Source: http://www.utvi.com. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
deadpresident blog updates
http://www.deadpresident.blogspot.com
Post Session Commentary - June 17 2008
Upmove continues, Sensex sizzles past 15,650
Higher advance tax payment, good monsoon lift spirits
India, China top outsourcing hubs
Reliance Industries, BGR Energy Systems, Cairn India, India Economy, Automobiles
NIIT Limited / Grasim Industries / Elecon Engineering, Ranbaxy Open Offer
Plethico Pharma /India Power Utilities /Education Sector
GAIL / ABG Shipyard, Anant Raj Industries, KPIT Cummins
Genus Power Infrastructure /Time Technoplast
Source: http://www.deadpresident.blogspot.com. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
Post Session Commentary - June 17 2008
Upmove continues, Sensex sizzles past 15,650
Higher advance tax payment, good monsoon lift spirits
India, China top outsourcing hubs
Reliance Industries, BGR Energy Systems, Cairn India, India Economy, Automobiles
NIIT Limited / Grasim Industries / Elecon Engineering, Ranbaxy Open Offer
Plethico Pharma /India Power Utilities /Education Sector
GAIL / ABG Shipyard, Anant Raj Industries, KPIT Cummins
Genus Power Infrastructure /Time Technoplast
Source: http://www.deadpresident.blogspot.com. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
16 June 2008
India Inc pays higher Q1 advance tax:UTVi
India Inc pays higher Q1 advance tax
India Inc today reported higher advance tax numbers for the first quarter of the current fiscal (Q1FY09).
ICICI Bank reported a 36% increase in advance tax payment at Rs 340 crore for Q1FY09 when compared with Rs 250 crore paid in the first quarter of the previous fiscal (Q1FY08).
SBI reported a 32% increase in advance tax payment at Rs 663 crore for Q1FY09 when compared with Rs 503 crore paid in Q1FY08.
IDBI advance tax payment was up 43% at Rs 10 crore for Q1FY09 as against Rs 7 crore paid in Q1FY08. Bank of Baroda has paid Rs 140 crore.
Reliance Industries has paid an advance tax of Rs 340 crore for Q1FY09 when compared with Rs 295 crore paid for Q1FY08.
While Ambuja Cements paid an advance tax of Rs 100 crore, Bajaj Buto paid a lower advance tax of Rs 50 crore for Q1FY09 when compared with Rs 60 crore paid for Q1FY08.
HDFC has paid an advance tax of Rs 140 crore for Q1FY09 when compared with Rs 95 crore in Q1FY08. Tata Motors has paid an advance tax of Rs 30 crore.
Other UTVi stories:
Daiichi may revise Ranbaxy offer price
Lehman Bros reports Q2 loss of $2.8 bn
No spectrum for MVNOs: Trai
VAT Panel seeks Rs4,000cr from Centre
Sensex ends up 206pts, ICICI Bk gains 4%
Buzzing stocks: Savita, Engineers India
No rate hikes likely now: Kochhar
Returns from stocks lower than FDs
MTN in India as Ambani guns blaze
Saudis to pump oil at fastest rate
Source: UTVi.com
India Inc today reported higher advance tax numbers for the first quarter of the current fiscal (Q1FY09).
ICICI Bank reported a 36% increase in advance tax payment at Rs 340 crore for Q1FY09 when compared with Rs 250 crore paid in the first quarter of the previous fiscal (Q1FY08).
SBI reported a 32% increase in advance tax payment at Rs 663 crore for Q1FY09 when compared with Rs 503 crore paid in Q1FY08.
IDBI advance tax payment was up 43% at Rs 10 crore for Q1FY09 as against Rs 7 crore paid in Q1FY08. Bank of Baroda has paid Rs 140 crore.
Reliance Industries has paid an advance tax of Rs 340 crore for Q1FY09 when compared with Rs 295 crore paid for Q1FY08.
While Ambuja Cements paid an advance tax of Rs 100 crore, Bajaj Buto paid a lower advance tax of Rs 50 crore for Q1FY09 when compared with Rs 60 crore paid for Q1FY08.
HDFC has paid an advance tax of Rs 140 crore for Q1FY09 when compared with Rs 95 crore in Q1FY08. Tata Motors has paid an advance tax of Rs 30 crore.
Other UTVi stories:
Daiichi may revise Ranbaxy offer price
Lehman Bros reports Q2 loss of $2.8 bn
No spectrum for MVNOs: Trai
VAT Panel seeks Rs4,000cr from Centre
Sensex ends up 206pts, ICICI Bk gains 4%
Buzzing stocks: Savita, Engineers India
No rate hikes likely now: Kochhar
Returns from stocks lower than FDs
MTN in India as Ambani guns blaze
Saudis to pump oil at fastest rate
Source: UTVi.com
ET Stories and The 10 top challenges for India
The 10 top challenges for India
India could be 40 times bigger by 2050, and may also have the potential to be larger than the US by that time. To achieve this, however, India needs to implement many changes. These are the findings of a global research report on ‘Ten Things for India to Achieve its 2050 Potential’, brought out by Jim O’Neill, Head Global Research at Goldman Sachs, and Tushar Poddar, V-P Research, Asia Economic Research Team at Goldman Sachs India. The reports lists a number of things for India to do, such as improving its governance, controlling inflation, introducing credible fiscal policy, liberalising financial markets and increasing trade with its neighbours. “Delivery of all these and more would ensure strong, persistent, medium-to-long-term growth, allowing India to reach its amazing potential,” it says. Here are the 10 top challenges for India:
1) Improve governance
Without better governance, delivery systems and effective implementation, India will find it difficult to educate its citizens, build its infrastructure, increase agricultural productivity and ensure that the fruits of economic growth are well established. Governance problems stem from the increasing inability of the government and public institutions to deliver public services in the face of rising expectations. A large gap between physical access to services and the quality of services provided is leading to a citizen satisfaction gap.
For more details, Visit @
The 10 top challenges for India
Other ET stories:
Bankers should shed conservatism in credit to entrepreneurs:FM
JSW Steel to set up steel plant in Georgia
Tata Steel to set up power plant in Orissa
Tata Tele-Virgin deal gets TRAI clean chit
Idea needs just three quarters to trunaround Spice
Oil falls, Saudi pushing output to highest since '81
Short covering on cards, resistance in 4700-4750 zones
BSE revises sectoral indices, PSU index
PINC puts 'buy' on Time Technoplast; target Rs 1,215
Maytas Infra bags Gulbarga airport project
Next leg of the bull run likely to begin soon
Avon Weighting System subscribed 45 times
HSBC launches insurance JV with Canara Bank and Oriental Bank
Investor's Guide
Techno wrap: Fast ride to nowhere
Royal Orchid Hotel: Walk on the red carpet
Metal market: Grab them while you can
Stocks to buy: OBC, Bhushan Steel, Pantaloon Retail, ABG Shipyard
Bharti Airtel attracts higher valuations than RCom
Mkt fall leaves a slew of undervalued stocks
More pain in store for European pharma
Lotus Eye Care Hospital's IPO: For the high 'n' mighty
IDFC Private Equity: Driving dreams
Derivatives diary: Beginning of the last bear market
Stock market still trading 25-30% higher
---------------------------------------------------------------------
Quarterly Results from www.Indiaearnings.com
Zee Entertainment FY08 net profit at Rs 416 cr
SREI Infra FY08 net profit at Rs 135 cr
Sunflag's Q4 FY08 PAT was at Rs 22 crore
Shipping Corp Q4 net profit at Rs 249 cr
NIIT Tech FY08 net profit up at Rs 135.26 cr
ABG Shipyard Q4 net profit at Rs 46 cr
Dhanalakshmi Bank Q4 FY08 PAT was at Rs 9.4cr
Karur Vysya Bank Q4 PAT was at Rs 70.5cr
HOV Services Q4 net profit was at Rs 31.7 cr
Source: www.theeconomictimes.com and www.indiaearnings.com. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
India could be 40 times bigger by 2050, and may also have the potential to be larger than the US by that time. To achieve this, however, India needs to implement many changes. These are the findings of a global research report on ‘Ten Things for India to Achieve its 2050 Potential’, brought out by Jim O’Neill, Head Global Research at Goldman Sachs, and Tushar Poddar, V-P Research, Asia Economic Research Team at Goldman Sachs India. The reports lists a number of things for India to do, such as improving its governance, controlling inflation, introducing credible fiscal policy, liberalising financial markets and increasing trade with its neighbours. “Delivery of all these and more would ensure strong, persistent, medium-to-long-term growth, allowing India to reach its amazing potential,” it says. Here are the 10 top challenges for India:
1) Improve governance
Without better governance, delivery systems and effective implementation, India will find it difficult to educate its citizens, build its infrastructure, increase agricultural productivity and ensure that the fruits of economic growth are well established. Governance problems stem from the increasing inability of the government and public institutions to deliver public services in the face of rising expectations. A large gap between physical access to services and the quality of services provided is leading to a citizen satisfaction gap.
For more details, Visit @
The 10 top challenges for India
Other ET stories:
Bankers should shed conservatism in credit to entrepreneurs:FM
JSW Steel to set up steel plant in Georgia
Tata Steel to set up power plant in Orissa
Tata Tele-Virgin deal gets TRAI clean chit
Idea needs just three quarters to trunaround Spice
Oil falls, Saudi pushing output to highest since '81
Short covering on cards, resistance in 4700-4750 zones
BSE revises sectoral indices, PSU index
PINC puts 'buy' on Time Technoplast; target Rs 1,215
Maytas Infra bags Gulbarga airport project
Next leg of the bull run likely to begin soon
Avon Weighting System subscribed 45 times
HSBC launches insurance JV with Canara Bank and Oriental Bank
Investor's Guide
Techno wrap: Fast ride to nowhere
Royal Orchid Hotel: Walk on the red carpet
Metal market: Grab them while you can
Stocks to buy: OBC, Bhushan Steel, Pantaloon Retail, ABG Shipyard
Bharti Airtel attracts higher valuations than RCom
Mkt fall leaves a slew of undervalued stocks
More pain in store for European pharma
Lotus Eye Care Hospital's IPO: For the high 'n' mighty
IDFC Private Equity: Driving dreams
Derivatives diary: Beginning of the last bear market
Stock market still trading 25-30% higher
---------------------------------------------------------------------
Quarterly Results from www.Indiaearnings.com
Zee Entertainment FY08 net profit at Rs 416 cr
SREI Infra FY08 net profit at Rs 135 cr
Sunflag's Q4 FY08 PAT was at Rs 22 crore
Shipping Corp Q4 net profit at Rs 249 cr
NIIT Tech FY08 net profit up at Rs 135.26 cr
ABG Shipyard Q4 net profit at Rs 46 cr
Dhanalakshmi Bank Q4 FY08 PAT was at Rs 9.4cr
Karur Vysya Bank Q4 PAT was at Rs 70.5cr
HOV Services Q4 net profit was at Rs 31.7 cr
Source: www.theeconomictimes.com and www.indiaearnings.com. We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
Reuters India Articles
http://in.reuters.com/money
Oil surges to new record high near $140 a barrel
Global dreams intensify Ambani family feud
Monsoon rains lash India, cover most of country
Govt revises duties on iron ore, steel
HSBC launches India insurance JV, eyes Asia growth
Indian shares rise 1.4 pct, Reliance Comm drops
Jet Airways to put global expansion on hold - exec
US STOCKS-Wall St opens lower on oil surge, data
Lehman loss matches forecast -- $2.8 billion
Bush wins European backing over Iran sanctions
Source: http://in.reuters.com . We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
Oil surges to new record high near $140 a barrel
Global dreams intensify Ambani family feud
Monsoon rains lash India, cover most of country
Govt revises duties on iron ore, steel
HSBC launches India insurance JV, eyes Asia growth
Indian shares rise 1.4 pct, Reliance Comm drops
Jet Airways to put global expansion on hold - exec
US STOCKS-Wall St opens lower on oil surge, data
Lehman loss matches forecast -- $2.8 billion
Bush wins European backing over Iran sanctions
Source: http://in.reuters.com . We thank (will be grateful to) the owners of the above articles/sites/sources/Govts for allowing/referring this. We are just providing the link/information of business updates from the leading sources for the benefit of readers. Viewers are strictly advised to take own decision in Stock buying and make verification about the information. Blog is not responsible for any faulty information.
Subscribe to:
Posts (Atom)